Acute exacerbation of idiopathic interstitial pneumonias
Conditions
Interventions
Intervention: recombinant soluble human thrombomodulin Control: Cases of acute exacerbation of idiopathic interstitial pneumonias treated in the past
Sponsors
NHO Kinki-Chuo Chest Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cases of acute exacerbation of chronic idiopathic interstitial pneumonias.
Exclusion criteria
Exclusion criteria: 1) Patients with major organ dysfunction. 2) Patients with fatal bleeding including intracranial bleeding, bleeding from gastrointestinal tracts, lung hemorrhage and so on. 3) Patients with high probability of fatal bleeding. 4) Patients with cerebral vascular diseases within one year. 5) Patients with intracranial damage caused by operations and external injury. 6) Pregnant or lactating woman, and woman with possibility of pregnancy. 7) Patients with apparent infection. 8) Patients within one month after surgery. 9) Patients with past history of hypersensitivity to thrombomodulin. 10) Patients improper to the trial according to the decision of a chief doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90 days survival compared with cases of acute exacerbation of idiopathic interstitial pneumonias treated in the past. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of serum markers, coagulation markers, arterial blood gas analysis and HRCT findings after the start of thrombomodulin are observed. Occurrence of bleeding and frequency of positive pressure ventilation are compared with control. | — |
Countries
Japan
Contacts
Public ContactToru Arai
NHO Kinki-Chuo Chest Medical Center Clinical Research Center
Outcome results
None listed